OTCMKTS:PHGUF Pharming Group (PHGUF) Stock Forecast, Price & News $1.30 0.00 (0.00%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$1.30▼$1.3050-Day Range$1.23▼$1.4052-Week Range$0.96▼$1.59VolumeN/AAverage Volume485 shsMarket Capitalization$848.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsHeadlinesShort InterestProfileChartCompetitorsEarningsHeadlinesShort Interest About Pharming Group (OTCMKTS:PHGUF) StockPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.Read More PHGUF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHGUF Stock News HeadlinesSeptember 22, 2023 | finance.yahoo.comPharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?September 9, 2023 | msn.comPharming Group: Pipeline Progresses With APDS Phase 3 InitiationOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 9, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Pharming Group (PHAR)August 9, 2023 | markets.businessinsider.comPharming Group NV American Depositary Shares Repr 10 Shs Reg SAugust 4, 2023 | msn.comPharming Group N.V. reports Q2 resultsMay 15, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Pharming Group (PHGUF)May 12, 2023 | msn.comPharming Group N.V. GAAP EPS of $0.02, revenue of $42.5M misses by $6MOctober 1, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.May 11, 2023 | benzinga.comPharming Group shares are trading lower after the company reported a year-over-year decrease in Q1 EPS and revenue.May 11, 2023 | markets.businessinsider.comPharming Group NV American Depositary Shares Repr 10 earnings: here's what Wall Street expectsMay 11, 2023 | finance.yahoo.comPharming Group reports financial results for the first quarter of 2023May 8, 2023 | finance.yahoo.comPharming Group's (AMS:PHARM) investors will be pleased with their decent 51% return over the last yearApril 26, 2023 | finanznachrichten.dePharming Group N.V.: Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023April 26, 2023 | finance.yahoo.comPharming to attend the H.C. Wainwright BioConnect Investor Conference 2023April 19, 2023 | finanznachrichten.dePharming Group: Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023April 19, 2023 | finanznachrichten.dePharming Group N.V.: Notice of First Quarter 2023 ResultsApril 19, 2023 | finance.yahoo.comNotice of First Quarter 2023 ResultsApril 19, 2023 | finance.yahoo.comPharming to attend the Van Lanschot Kempen Life Sciences Conference 2023April 11, 2023 | finance.yahoo.comPharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.April 5, 2023 | finance.yahoo.comPharming Group announces the filing of its 2022 Annual Report and Form 20-FMarch 30, 2023 | finance.yahoo.comPharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease DaysMarch 27, 2023 | finance.yahoo.comFDA Approves Pharming's Immune Disorder Drug, As First APDS TherapyMarch 13, 2023 | finance.yahoo.comPharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcementFebruary 28, 2023 | finanznachrichten.dePharming Group N.V.: Notice of Full Year 2022 financial resultsFebruary 28, 2023 | finance.yahoo.comNotice of Full Year 2022 financial resultsFebruary 21, 2023 | finanznachrichten.dePharming Group N.V.: Pharming announces first patient enrolled in pediatric clinical trial of leniolisibSee More Headlines Receive PHGUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGUF Company Calendar Last Earnings3/05/2015Today10/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PHGUF Previous SymbolOTC:PHGUF CUSIPN/A CIKN/A Webwww.pharming.com Phone(171) 524-7400Fax31-0-71-524-7445Employees332Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$13.67 million Net Margins-7.96% Pretax Margin7.29% Return on Equity-8.15% Return on Assets-4.00% Debt Debt-to-Equity Ratio0.83 Current Ratio4.51 Quick Ratio3.69 Sales & Book Value Annual Sales$205.62 million Price / Sales4.12 Cash Flow$0.04 per share Price / Cash Flow31.57 Book Value$0.31 per share Price / Book4.19Miscellaneous Outstanding Shares652,410,000Free FloatN/AMarket Cap$848.13 million OptionableNot Optionable Beta1.10 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Sijmen de Vries M.B.A. (Age 64)M.D., MBA, Pres, CEO & Exec. Director Comp: $1.18MMr. Jeroen Wakkerman (Age 54)Chief Financial Officer Ms. Mireille Sanders M.Sc. (Age 55)Chief Operations Officer Susanne EmbletonInvestor Relations Mang.Mr. Ruud Van Outersterp (Age 59)Chief Ethics & Compliance Officer Dr. Anurag Relan M.D. (Age 51)MPH, Chief Medical Officer Mr. Stephen Toor (Age 52)Chief Commercial Officer & GM Americas Dr. Alexander Breidenbach M.B.A.Chief Bus. OfficerDr. Bruno M. L. Giannetti (Age 71)Consultant More ExecutivesKey CompetitorsAcelyrinNASDAQ:SLRNArdelyxNASDAQ:ARDXKeros TherapeuticsNASDAQ:KROSInnovivaNASDAQ:INVABelite BioNASDAQ:BLTEView All Competitors PHGUF Stock - Frequently Asked Questions How have PHGUF shares performed in 2023? Pharming Group's stock was trading at $1.1499 at the beginning of 2023. Since then, PHGUF stock has increased by 13.1% and is now trading at $1.30. View the best growth stocks for 2023 here. How were Pharming Group's earnings last quarter? Pharming Group (OTCMKTS:PHGUF) issued its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative trailing twelve-month return on equity of 8.15% and a negative net margin of 7.96%. What is Pharming Group's stock symbol? Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF." How do I buy shares of Pharming Group? Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pharming Group's stock price today? One share of PHGUF stock can currently be purchased for approximately $1.30. How much money does Pharming Group make? Pharming Group (OTCMKTS:PHGUF) has a market capitalization of $848.13 million and generates $205.62 million in revenue each year. The biotechnology company earns $13.67 million in net income (profit) each year or ($0.03) on an earnings per share basis. How many employees does Pharming Group have? The company employs 332 workers across the globe. How can I contact Pharming Group? Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The official website for the company is www.pharming.com. The biotechnology company can be reached via phone at (171) 524-7400, via email at investor@pharming.com, or via fax at 31-0-71-524-7445. This page (OTCMKTS:PHGUF) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.